Shu Y - Search Results

1

HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma.

Xu T, Fang Y, Gu Y, Xu D, Hu T, Yu T, Xu YY, Shen HY, Ma P, Shu Y. Xu T, et al. Among authors: shu y. J Immunother Cancer. 2024 Oct 9;12(10):e010077. doi: 10.1136/jitc-2024-010077. J Immunother Cancer. 2024. PMID: 39384195 Free PMC article.

2

Pyroptosis: A new frontier in cancer.

Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, Yu T, Wu X, Shi Y, Ma P, Shu Y. Fang Y, et al. Among authors: shu y. Biomed Pharmacother. 2020 Jan;121:109595. doi: 10.1016/j.biopha.2019.109595. Epub 2019 Nov 9. Biomed Pharmacother. 2020. PMID: 31710896 Free article. Review.

3

Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation.

Xie M, Yu T, Jing X, Ma L, Fan Y, Yang F, Ma P, Jiang H, Wu X, Shu Y, Xu T. Xie M, et al. Among authors: shu y. Mol Cancer. 2020 Jun 29;19(1):112. doi: 10.1186/s12943-020-01208-3. Mol Cancer. 2020. PMID: 32600329 Free PMC article.

4

The evolving landscape of N⁶-methyladenosine modification in the tumor microenvironment.

Gu Y, Wu X, Zhang J, Fang Y, Pan Y, Shu Y, Ma P. Gu Y, et al. Among authors: shu y. Mol Ther. 2021 May 5;29(5):1703-1715. doi: 10.1016/j.ymthe.2021.04.009. Epub 2021 Apr 9. Mol Ther. 2021. PMID: 33839323 Free PMC article. Review.

5

Hsa_circ_0007967 promotes gastric cancer proliferation through the miR-411-5p/MAML3 axis.

Zha Q, Wu X, Zhang J, Xu T, Shi Y, Sun Y, Fang Y, Gu Y, Ma P, Shu Y, Tian S. Zha Q, et al. Among authors: shu y. Cell Death Discov. 2022 Mar 30;8(1):144. doi: 10.1038/s41420-022-00954-1. Cell Death Discov. 2022. PMID: 35354791 Free PMC article.

6

Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53.

Jing X, Xie M, Ding K, Xu T, Fang Y, Ma P, Shu Y. Jing X, et al. Among authors: shu y. Clin Transl Med. 2022 May;12(5):e780. doi: 10.1002/ctm2.780. Clin Transl Med. 2022. PMID: 35522909 Free PMC article.

7

Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.

Ma P, Huang R, Gu Y, Fang Y, Wu X, Chen DS, Zhang HW, Gao W, Shu Y. Ma P, et al. Among authors: shu y. Anticancer Drugs. 2022 Nov 1;33(10):1186-1190. doi: 10.1097/CAD.0000000000001370. Epub 2022 Aug 10. Anticancer Drugs. 2022. PMID: 35946569

8

LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA.

Xu TP, Yu T, Xie MY, Fang Y, Xu TT, Pan YT, Ma P, Shu YQ. Xu TP, et al. Among authors: shu yq. Gastric Cancer. 2023 Mar;26(2):169-186. doi: 10.1007/s10120-022-01348-z. Epub 2022 Oct 25. Gastric Cancer. 2023. PMID: 36284068

9

Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.

He J, Ma P, Zhao D, Shi X, Guo R, Gao W, Shu Y. He J, et al. Among authors: shu y. Cancer. 2023 May 15;129(10):1513-1522. doi: 10.1002/cncr.34697. Epub 2023 Feb 22. Cancer. 2023. PMID: 36813747 Free article. Clinical Trial.

10

LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m⁶ A-YTHDF2-dependent manner.

Fang Y, Wu X, Gu Y, Shi R, Yu T, Pan Y, Zhang J, Jing X, Ma P, Shu Y. Fang Y, et al. Among authors: shu y. Clin Transl Med. 2023 Mar;13(3):e1205. doi: 10.1002/ctm2.1205. Clin Transl Med. 2023. PMID: 36864711 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,839 results

Search Page

Filters